VREX Stock Analysis: Varex Imaging | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 769m USD | 12M Return: 58.4% | US92214X1063 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 11.5M
EPS Trend: -11.5%
Qual. Beats: 1
Rev. Trend: -19.7%
Qual. Beats: -1
Warnings
Tailwinds
Seasonality 9.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Varex Imaging Corporation (NASDAQ: VREX) designs, manufactures, and sells X-ray imaging components, operating through two segments: Medical and Industrial. The company was incorporated in 2016 and is headquartered in Salt Lake City, Utah, with a global footprint spanning North America, Latin America, Europe, the Middle East, India, Africa, Asia, and Australia.
The Medical segment provides a broad portfolio of X-ray imaging components-including X-ray tubes, digital detectors, image-processing software, generators, and related accessories-used in CT, mammography, oncology, cardiac, surgery, dental, and other diagnostic radiography applications. The Industrial segment supplies Linatron X-ray linear accelerators, non-intrusive cargo inspection systems, and related components for security and inspection uses such as airport baggage screening, port and border cargo screening, and nondestructive testing.
Varex sells its products through imaging system original equipment manufacturers (OEMs), independent service companies, distributors, and directly to end-users. As a component supplier in the medical imaging value chain, Varex serves both healthcare OEMs (e.g., CT, mammography, and dental systems) and security/inspection integrators. Classified within the GICS Health Care Equipment sub-industry, Varex reported a market capitalization of approximately $784 million and has been listed on NASDAQ since its January 2017 IPO.
- Medical segment revenue grows on CT tube replacement demand
- Industrial cargo inspection orders tied to airport security spending
- Pricing competition in digital detectors pressures Medical margins
| Net Income: 22.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA -5.23 > 1.0 |
| NWC/Revenue: 51.53% < 20% (prev 53.91%; Δ -2.38% < -1%) |
| CFO/TA 0.01 > 3% & CFO 11.3m > Net Income 22.1m |
| Net Debt (300.9m) to EBITDA (93.9m): 3.20 < 3 |
| Current Ratio: 3.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (42.6m) vs 12m ago 2.65% < -2% |
| Gross Margin: 34.32% > 18% (prev 34.06%; Δ 0.26% > 0.5%) |
| Asset Turnover: 79.60% > 50% (prev 76.52%; Δ 3.08% > 0%) |
| Interest Coverage Ratio: 1.71 > 6 (EBIT TTM 66.6m / Interest Expense TTM 38.9m) |
| A: 0.41 (Total Current Assets 633.1m - Total Current Liabilities 187.4m) / Total Assets 1.10b |
| B: 0.00 (Retained Earnings 4.00m / Total Assets 1.10b) |
| C: 0.06 (EBIT TTM 66.6m / Avg Total Assets 1.09b) |
| D: 0.84 (Book Value of Equity 496.6m / Total Liabilities 589.5m) |
| Altman-Z'' = 3.97 = AA |
| DSRI: 1.00 (Receivables 144.7m/137.8m, Revenue 865.0m/821.4m) |
| GMI: 0.99 (GM 34.06% / 34.32%) |
| AQI: 1.05 (AQ_t 0.27 / AQ_t-1 0.26) |
| SGI: 1.05 (Revenue 865.0m / 821.4m) |
| TATA: 0.01 (NI 22.1m - CFO 11.3m) / TA 1.10b) |
| Beneish M = -2.97 (Cap -4..+1) = A |
As of November 18, 2026, the stock is trading at USD 18.10 with a total of 1,241,307 shares traded. Over the past week, the price has changed by -1.90%, over one month by -1.63%, over three months by -1.95% and over the past year by +58.36%.
Current recommended Stop Loss: 17.90 (which is 1.1% or 2.2 ATR below the current price).
Varex Imaging has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold VREX.
- StrongBuy: 0
- Buy: 0
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 18.9 | 4.4% |
P/E Trailing = 34.1792
P/E Forward = 19.9203
P/S = 0.8893
P/B = 1.5503
P/EG = 6.2987
Revenue TTM = 865.0m USD
EBIT TTM = 66.6m USD
EBITDA TTM = 93.9m USD
Long Term Debt = 328.9m USD (from longTermDebt, last quarter)
Short Term Debt = 22.7m USD (from shortTermDebt, last quarter)
Debt = 400.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 26.5m
Net Debt = 300.9m USD (calculated: Debt 400.1m - CCE 99.2m)
Enterprise Value = 1.07b USD (769.2m + Debt 400.1m - CCE 99.2m)
Interest Coverage Ratio = 1.71 (Ebit TTM 66.6m / Interest Expense TTM 38.9m)
EV/FCF = -52.98x (Enterprise Value 1.07b / FCF TTM -20.2m)
FCF Yield = -1.89% (FCF TTM -20.2m / Enterprise Value 1.07b)
FCF Margin = -2.34% (FCF TTM -20.2m / Revenue TTM 865.0m)
Net Margin = 2.55% (Net Income TTM 22.1m / Revenue TTM 865.0m)
Gross Margin = 34.32% ((Revenue TTM 865.0m - Cost of Revenue TTM 568.1m) / Revenue TTM)
Gross Margin QoQ = 36.44% (prev 33.61%)
Tobins Q-Ratio = 0.97 (Enterprise Value 1.07b / Total Assets 1.10b)
Interest Expense / Debt = 9.72% (Interest Expense 38.9m / Debt 400.1m)
Taxrate = 18.77% (5.20m / 27.7m)
NOPAT = 54.1m (EBIT 66.6m * (1 - 18.77%))
Current Ratio = 3.38 (Total Current Assets 633.1m / Total Current Liabilities 187.4m)
Debt / Equity = 0.81 (Debt 400.1m / totalStockholderEquity, last quarter 496.6m)
Debt / EBITDA = 3.20 (Net Debt 300.9m / EBITDA 93.9m)
Debt / FCF = -14.90 (negative FCF - burning cash) (Net Debt 300.9m / FCF TTM -20.2m)
Total Stockholder Equity = 480.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.03% (Net Income 22.1m / Total Assets 1.10b)
RoE = 4.60% (Net Income TTM 22.1m / Total Stockholder Equity 480.1m)
RoCE = 8.23% (EBIT 66.6m / Capital Employed (Equity 480.1m + L.T.Debt 328.9m))
RoIC = 6.06% (NOPAT 54.1m / Invested Capital 892.0m)
WACC = 10.21% (E(769.2m)/V(1.17b) * Re(11.41%) + D(400.1m)/V(1.17b) * Rd(9.72%) * (1-Tc(0.19)))
Discount Rate = 11.41% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 10.34 | Cagr: 1.50%
[DCF] Fair Price = unknown (Cash Flow -20.2m)
EPS Correlation: -11.54 | EPS CAGR: -3.53% | SUE: 1.14 | # QB: 1
Revenue Correlation: -19.69 | Revenue CAGR: -0.64% | SUE: -0.92 | # QB: -1
EPS current Quarter (2026-12-31): EPS=0.18 | Chg30d=-10.00% | Revisions=+25% | Analysts=1
EPS current Year (2026-09-30): EPS=0.84 | Chg30d=+7.97% | Revisions=+57% | GrowthEPS=-6.7% | GrowthRev=+2.5%
EPS next Year (2027-09-30): EPS=1.07 | Chg30d=+0.56% | Revisions=+0% | GrowthEPS=+27.4% | GrowthRev=+4.0%
[Analyst] Revisions Ratio: +50% (up=6, down=1)